nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—pancreatitis	0.455	0.678	CbGaD
Thalidomide—PTGS2—pancreatitis	0.216	0.322	CbGaD
Thalidomide—Enuresis—Hyoscyamine—pancreatitis	0.00565	0.0537	CcSEcCtD
Thalidomide—FGFR2—exocrine gland—pancreatitis	0.00469	0.118	CbGeAlD
Thalidomide—TNF—blood—pancreatitis	0.00346	0.0871	CbGeAlD
Thalidomide—NFKB1—islet of Langerhans—pancreatitis	0.00344	0.0869	CbGeAlD
Thalidomide—CRBN—islet of Langerhans—pancreatitis	0.00289	0.0728	CbGeAlD
Thalidomide—Menadione—XDH—pancreatitis	0.00235	0.345	CrCbGaD
Thalidomide—Cyanosis—Hyoscyamine—pancreatitis	0.00228	0.0217	CcSEcCtD
Thalidomide—Pomalidomide—TNF—pancreatitis	0.00225	0.33	CrCbGaD
Thalidomide—Stupor—Hyoscyamine—pancreatitis	0.00216	0.0205	CcSEcCtD
Thalidomide—NFKB1—digestive system—pancreatitis	0.00207	0.0522	CbGeAlD
Thalidomide—CRBN—pancreas—pancreatitis	0.00203	0.0512	CbGeAlD
Thalidomide—Abdominal distension—Propantheline—pancreatitis	0.00199	0.0189	CcSEcCtD
Thalidomide—Dysphagia—Propantheline—pancreatitis	0.00198	0.0188	CcSEcCtD
Thalidomide—NFKB1—blood—pancreatitis	0.00197	0.0497	CbGeAlD
Thalidomide—Petechiae—Hyoscyamine—pancreatitis	0.00196	0.0186	CcSEcCtD
Thalidomide—Blood disorder—Hyoscyamine—pancreatitis	0.00193	0.0184	CcSEcCtD
Thalidomide—Erectile dysfunction—Propantheline—pancreatitis	0.00182	0.0173	CcSEcCtD
Thalidomide—Drowsiness—Propantheline—pancreatitis	0.00176	0.0168	CcSEcCtD
Thalidomide—CRBN—digestive system—pancreatitis	0.00173	0.0437	CbGeAlD
Thalidomide—Leukocytosis—Hyoscyamine—pancreatitis	0.00172	0.0163	CcSEcCtD
Thalidomide—CRBN—blood—pancreatitis	0.00165	0.0416	CbGeAlD
Thalidomide—Depressed level of consciousness—Hyoscyamine—pancreatitis	0.00156	0.0148	CcSEcCtD
Thalidomide—FGFR2—digestive system—pancreatitis	0.00155	0.0392	CbGeAlD
Thalidomide—Skin exfoliation—Hyoscyamine—pancreatitis	0.00154	0.0146	CcSEcCtD
Thalidomide—Blood urea increased—Hyoscyamine—pancreatitis	0.00152	0.0145	CcSEcCtD
Thalidomide—Dry eye—Hyoscyamine—pancreatitis	0.00149	0.0142	CcSEcCtD
Thalidomide—FGFR2—blood—pancreatitis	0.00148	0.0373	CbGeAlD
Thalidomide—Rash maculo-papular—Hyoscyamine—pancreatitis	0.00147	0.0139	CcSEcCtD
Thalidomide—Pulmonary oedema—Hyoscyamine—pancreatitis	0.00144	0.0137	CcSEcCtD
Thalidomide—Hypertonia—Hyoscyamine—pancreatitis	0.00142	0.0134	CcSEcCtD
Thalidomide—Hyperkinesia—Hyoscyamine—pancreatitis	0.00141	0.0134	CcSEcCtD
Thalidomide—Tension—Propantheline—pancreatitis	0.00135	0.0129	CcSEcCtD
Thalidomide—Nervousness—Propantheline—pancreatitis	0.00134	0.0127	CcSEcCtD
Thalidomide—Eczema—Hyoscyamine—pancreatitis	0.0013	0.0124	CcSEcCtD
Thalidomide—Vision blurred—Propantheline—pancreatitis	0.0013	0.0123	CcSEcCtD
Thalidomide—Eye pain—Hyoscyamine—pancreatitis	0.0013	0.0123	CcSEcCtD
Thalidomide—Amnesia—Hyoscyamine—pancreatitis	0.00125	0.0119	CcSEcCtD
Thalidomide—Atrial fibrillation—Hyoscyamine—pancreatitis	0.00124	0.0117	CcSEcCtD
Thalidomide—Palpitations—Propantheline—pancreatitis	0.00122	0.0116	CcSEcCtD
Thalidomide—Hypoglycaemia—Hyoscyamine—pancreatitis	0.0012	0.0114	CcSEcCtD
Thalidomide—PTGS2—gall bladder—pancreatitis	0.0012	0.0302	CbGeAlD
Thalidomide—Lethargy—Hyoscyamine—pancreatitis	0.0012	0.0114	CcSEcCtD
Thalidomide—Hyponatraemia—Hyoscyamine—pancreatitis	0.00118	0.0112	CcSEcCtD
Thalidomide—Osteoarthritis—Hyoscyamine—pancreatitis	0.00117	0.0111	CcSEcCtD
Thalidomide—Lenalidomide—PTGS2—pancreatitis	0.00115	0.169	CrCbGaD
Thalidomide—Dry mouth—Propantheline—pancreatitis	0.00115	0.0109	CcSEcCtD
Thalidomide—Psychotic disorder—Hyoscyamine—pancreatitis	0.00114	0.0109	CcSEcCtD
Thalidomide—Confusional state—Propantheline—pancreatitis	0.00113	0.0108	CcSEcCtD
Thalidomide—Cardiac arrest—Hyoscyamine—pancreatitis	0.00111	0.0106	CcSEcCtD
Thalidomide—Ataxia—Hyoscyamine—pancreatitis	0.0011	0.0105	CcSEcCtD
Thalidomide—Tachycardia—Propantheline—pancreatitis	0.0011	0.0104	CcSEcCtD
Thalidomide—Dehydration—Hyoscyamine—pancreatitis	0.00109	0.0104	CcSEcCtD
Thalidomide—Dry skin—Hyoscyamine—pancreatitis	0.00107	0.0102	CcSEcCtD
Thalidomide—Pomalidomide—PTGS2—pancreatitis	0.00107	0.157	CrCbGaD
Thalidomide—Hypokalaemia—Hyoscyamine—pancreatitis	0.00107	0.0101	CcSEcCtD
Thalidomide—Abdominal distension—Hyoscyamine—pancreatitis	0.00102	0.00969	CcSEcCtD
Thalidomide—Insomnia—Propantheline—pancreatitis	0.00102	0.00967	CcSEcCtD
Thalidomide—Dysphagia—Hyoscyamine—pancreatitis	0.00101	0.00962	CcSEcCtD
Thalidomide—Somnolence—Propantheline—pancreatitis	0.001	0.0095	CcSEcCtD
Thalidomide—Angina pectoris—Hyoscyamine—pancreatitis	0.000987	0.00937	CcSEcCtD
Thalidomide—Constipation—Propantheline—pancreatitis	0.000962	0.00914	CcSEcCtD
Thalidomide—Erectile dysfunction—Hyoscyamine—pancreatitis	0.000933	0.00886	CcSEcCtD
Thalidomide—Feeling abnormal—Propantheline—pancreatitis	0.000927	0.00881	CcSEcCtD
Thalidomide—CYP3A5—islet of Langerhans—pancreatitis	0.000915	0.0231	CbGeAlD
Thalidomide—Hyperglycaemia—Hyoscyamine—pancreatitis	0.000914	0.00868	CcSEcCtD
Thalidomide—Drowsiness—Hyoscyamine—pancreatitis	0.000903	0.00858	CcSEcCtD
Thalidomide—Depression—Hyoscyamine—pancreatitis	0.0009	0.00856	CcSEcCtD
Thalidomide—Urticaria—Propantheline—pancreatitis	0.000894	0.00849	CcSEcCtD
Thalidomide—Acute coronary syndrome—Hyoscyamine—pancreatitis	0.00089	0.00846	CcSEcCtD
Thalidomide—Myocardial infarction—Hyoscyamine—pancreatitis	0.000885	0.00841	CcSEcCtD
Thalidomide—Conjunctivitis—Hyoscyamine—pancreatitis	0.000878	0.00834	CcSEcCtD
Thalidomide—Sweating—Hyoscyamine—pancreatitis	0.000866	0.00823	CcSEcCtD
Thalidomide—Hypersensitivity—Propantheline—pancreatitis	0.000829	0.00788	CcSEcCtD
Thalidomide—Bradycardia—Hyoscyamine—pancreatitis	0.000825	0.00784	CcSEcCtD
Thalidomide—Asthenia—Propantheline—pancreatitis	0.000807	0.00767	CcSEcCtD
Thalidomide—PTGS2—islet of Langerhans—pancreatitis	0.000786	0.0198	CbGeAlD
Thalidomide—Dizziness—Propantheline—pancreatitis	0.000744	0.00707	CcSEcCtD
Thalidomide—Arrhythmia—Hyoscyamine—pancreatitis	0.000724	0.00688	CcSEcCtD
Thalidomide—Vomiting—Propantheline—pancreatitis	0.000715	0.0068	CcSEcCtD
Thalidomide—Mental disorder—Hyoscyamine—pancreatitis	0.00071	0.00675	CcSEcCtD
Thalidomide—Rash—Propantheline—pancreatitis	0.000709	0.00674	CcSEcCtD
Thalidomide—Dermatitis—Propantheline—pancreatitis	0.000709	0.00673	CcSEcCtD
Thalidomide—Headache—Propantheline—pancreatitis	0.000705	0.0067	CcSEcCtD
Thalidomide—CYP2C19—digestive system—pancreatitis	0.000698	0.0176	CbGeAlD
Thalidomide—Tension—Hyoscyamine—pancreatitis	0.000693	0.00658	CcSEcCtD
Thalidomide—Dysgeusia—Hyoscyamine—pancreatitis	0.000691	0.00657	CcSEcCtD
Thalidomide—Nervousness—Hyoscyamine—pancreatitis	0.000685	0.00651	CcSEcCtD
Thalidomide—Nausea—Propantheline—pancreatitis	0.000668	0.00635	CcSEcCtD
Thalidomide—Vision blurred—Hyoscyamine—pancreatitis	0.000665	0.00632	CcSEcCtD
Thalidomide—CYP2C19—blood—pancreatitis	0.000665	0.0168	CbGeAlD
Thalidomide—Agitation—Hyoscyamine—pancreatitis	0.000649	0.00616	CcSEcCtD
Thalidomide—Angioedema—Hyoscyamine—pancreatitis	0.000645	0.00613	CcSEcCtD
Thalidomide—CYP3A5—pancreas—pancreatitis	0.000643	0.0162	CbGeAlD
Thalidomide—Vertigo—Hyoscyamine—pancreatitis	0.000634	0.00602	CcSEcCtD
Thalidomide—Syncope—Hyoscyamine—pancreatitis	0.000633	0.00601	CcSEcCtD
Thalidomide—Palpitations—Hyoscyamine—pancreatitis	0.000624	0.00593	CcSEcCtD
Thalidomide—Loss of consciousness—Hyoscyamine—pancreatitis	0.00062	0.00589	CcSEcCtD
Thalidomide—Convulsion—Hyoscyamine—pancreatitis	0.000611	0.00581	CcSEcCtD
Thalidomide—Chest pain—Hyoscyamine—pancreatitis	0.000601	0.00571	CcSEcCtD
Thalidomide—Anxiety—Hyoscyamine—pancreatitis	0.000599	0.00569	CcSEcCtD
Thalidomide—Dry mouth—Hyoscyamine—pancreatitis	0.000588	0.00558	CcSEcCtD
Thalidomide—Confusional state—Hyoscyamine—pancreatitis	0.000581	0.00552	CcSEcCtD
Thalidomide—Oedema—Hyoscyamine—pancreatitis	0.000576	0.00547	CcSEcCtD
Thalidomide—CYP1A2—digestive system—pancreatitis	0.00057	0.0144	CbGeAlD
Thalidomide—Shock—Hyoscyamine—pancreatitis	0.000567	0.00538	CcSEcCtD
Thalidomide—Tachycardia—Hyoscyamine—pancreatitis	0.000562	0.00534	CcSEcCtD
Thalidomide—CYP1A1—digestive system—pancreatitis	0.000562	0.0142	CbGeAlD
Thalidomide—Hyperhidrosis—Hyoscyamine—pancreatitis	0.000557	0.00529	CcSEcCtD
Thalidomide—PTGS2—pancreas—pancreatitis	0.000553	0.0139	CbGeAlD
Thalidomide—CYP3A5—digestive system—pancreatitis	0.00055	0.0139	CbGeAlD
Thalidomide—CYP1A2—blood—pancreatitis	0.000543	0.0137	CbGeAlD
Thalidomide—CYP2C9—digestive system—pancreatitis	0.000541	0.0136	CbGeAlD
Thalidomide—Hypotension—Hyoscyamine—pancreatitis	0.000538	0.00511	CcSEcCtD
Thalidomide—CYP1A1—blood—pancreatitis	0.000535	0.0135	CbGeAlD
Thalidomide—CYP3A5—blood—pancreatitis	0.000524	0.0132	CbGeAlD
Thalidomide—Insomnia—Hyoscyamine—pancreatitis	0.000521	0.00495	CcSEcCtD
Thalidomide—CYP2C9—blood—pancreatitis	0.000515	0.013	CbGeAlD
Thalidomide—Dyspnoea—Hyoscyamine—pancreatitis	0.000513	0.00488	CcSEcCtD
Thalidomide—CYP2E1—digestive system—pancreatitis	0.000513	0.0129	CbGeAlD
Thalidomide—Somnolence—Hyoscyamine—pancreatitis	0.000512	0.00486	CcSEcCtD
Thalidomide—Dyspepsia—Hyoscyamine—pancreatitis	0.000507	0.00482	CcSEcCtD
Thalidomide—Fatigue—Hyoscyamine—pancreatitis	0.000497	0.00472	CcSEcCtD
Thalidomide—PTGS1—digestive system—pancreatitis	0.000494	0.0125	CbGeAlD
Thalidomide—Pain—Hyoscyamine—pancreatitis	0.000493	0.00468	CcSEcCtD
Thalidomide—Constipation—Hyoscyamine—pancreatitis	0.000493	0.00468	CcSEcCtD
Thalidomide—CYP2E1—blood—pancreatitis	0.000488	0.0123	CbGeAlD
Thalidomide—Feeling abnormal—Hyoscyamine—pancreatitis	0.000475	0.00451	CcSEcCtD
Thalidomide—PTGS2—digestive system—pancreatitis	0.000472	0.0119	CbGeAlD
Thalidomide—Gastrointestinal pain—Hyoscyamine—pancreatitis	0.000471	0.00447	CcSEcCtD
Thalidomide—PTGS1—blood—pancreatitis	0.00047	0.0119	CbGeAlD
Thalidomide—Urticaria—Hyoscyamine—pancreatitis	0.000458	0.00435	CcSEcCtD
Thalidomide—Abdominal pain—Hyoscyamine—pancreatitis	0.000455	0.00433	CcSEcCtD
Thalidomide—Body temperature increased—Hyoscyamine—pancreatitis	0.000455	0.00433	CcSEcCtD
Thalidomide—PTGS2—blood—pancreatitis	0.00045	0.0113	CbGeAlD
Thalidomide—Hypersensitivity—Hyoscyamine—pancreatitis	0.000424	0.00403	CcSEcCtD
Thalidomide—Asthenia—Hyoscyamine—pancreatitis	0.000413	0.00393	CcSEcCtD
Thalidomide—Pruritus—Hyoscyamine—pancreatitis	0.000407	0.00387	CcSEcCtD
Thalidomide—Diarrhoea—Hyoscyamine—pancreatitis	0.000394	0.00374	CcSEcCtD
Thalidomide—Dizziness—Hyoscyamine—pancreatitis	0.000381	0.00362	CcSEcCtD
Thalidomide—Vomiting—Hyoscyamine—pancreatitis	0.000366	0.00348	CcSEcCtD
Thalidomide—Rash—Hyoscyamine—pancreatitis	0.000363	0.00345	CcSEcCtD
Thalidomide—Dermatitis—Hyoscyamine—pancreatitis	0.000363	0.00345	CcSEcCtD
Thalidomide—Headache—Hyoscyamine—pancreatitis	0.000361	0.00343	CcSEcCtD
Thalidomide—Nausea—Hyoscyamine—pancreatitis	0.000342	0.00325	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—SMO—pancreatitis	2.75e-05	0.000155	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTHLH—pancreatitis	2.75e-05	0.000155	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CTRB2—pancreatitis	2.75e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—pancreatitis	2.75e-05	0.000155	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—pancreatitis	2.71e-05	0.000153	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGB—pancreatitis	2.7e-05	0.000152	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—pancreatitis	2.68e-05	0.000151	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—XDH—pancreatitis	2.68e-05	0.000151	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—MDM2—pancreatitis	2.68e-05	0.000151	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SST—pancreatitis	2.66e-05	0.00015	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PNLIP—pancreatitis	2.65e-05	0.00015	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PRSS3—pancreatitis	2.65e-05	0.00015	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—DUSP6—pancreatitis	2.63e-05	0.000149	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PPP3CA—pancreatitis	2.63e-05	0.000148	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—FDX1—pancreatitis	2.62e-05	0.000148	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—pancreatitis	2.59e-05	0.000146	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—pancreatitis	2.57e-05	0.000145	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G1B—pancreatitis	2.53e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—XDH—pancreatitis	2.52e-05	0.000142	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SST—pancreatitis	2.52e-05	0.000142	CbGpPWpGaD
Thalidomide—FGFR2—Disease—LPL—pancreatitis	2.52e-05	0.000142	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—XDH—pancreatitis	2.52e-05	0.000142	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PLA2G1B—pancreatitis	2.51e-05	0.000142	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADH1B—pancreatitis	2.5e-05	0.000141	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—DUSP6—pancreatitis	2.5e-05	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BDKRB2—pancreatitis	2.5e-05	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—pancreatitis	2.5e-05	0.000141	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CRP—pancreatitis	2.46e-05	0.000139	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CNR1—pancreatitis	2.45e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—A2M—pancreatitis	2.44e-05	0.000138	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH4—pancreatitis	2.43e-05	0.000137	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—A2M—pancreatitis	2.42e-05	0.000137	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—FDX1—pancreatitis	2.39e-05	0.000135	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—XDH—pancreatitis	2.38e-05	0.000134	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BDKRB2—pancreatitis	2.37e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GCG—pancreatitis	2.37e-05	0.000134	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—TLR4—pancreatitis	2.36e-05	0.000133	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HLA-DRB1—pancreatitis	2.36e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CTRB2—pancreatitis	2.35e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADH1B—pancreatitis	2.35e-05	0.000133	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—LPL—pancreatitis	2.35e-05	0.000133	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADH1B—pancreatitis	2.35e-05	0.000132	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatitis	2.34e-05	0.000132	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CRP—pancreatitis	2.33e-05	0.000132	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CNR1—pancreatitis	2.33e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—pancreatitis	2.32e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRSS1—pancreatitis	2.29e-05	0.000129	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KNG1—pancreatitis	2.27e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ICAM1—pancreatitis	2.26e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GCG—pancreatitis	2.25e-05	0.000127	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR4—pancreatitis	2.24e-05	0.000126	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HLA-DRB1—pancreatitis	2.24e-05	0.000126	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH4—pancreatitis	2.22e-05	0.000125	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALDH2—pancreatitis	2.22e-05	0.000125	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADH1B—pancreatitis	2.22e-05	0.000125	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—pancreatitis	2.2e-05	0.000124	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—pancreatitis	2.18e-05	0.000123	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PNLIP—pancreatitis	2.17e-05	0.000122	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRSS3—pancreatitis	2.17e-05	0.000122	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—pancreatitis	2.17e-05	0.000122	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—pancreatitis	2.16e-05	0.000122	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	2.16e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KNG1—pancreatitis	2.16e-05	0.000122	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—pancreatitis	2.15e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ICAM1—pancreatitis	2.15e-05	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—pancreatitis	2.12e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGA—pancreatitis	2.1e-05	0.000119	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—pancreatitis	2.09e-05	0.000118	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PDGFA—pancreatitis	2.09e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRSS1—pancreatitis	2.09e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—LPL—pancreatitis	2.09e-05	0.000118	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—FDX1—pancreatitis	2.04e-05	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—pancreatitis	2.01e-05	0.000113	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLA2G1B—pancreatitis	1.99e-05	0.000112	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PDGFA—pancreatitis	1.98e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRSS3—pancreatitis	1.98e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PNLIP—pancreatitis	1.98e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—XDH—pancreatitis	1.95e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.94e-05	0.00011	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—A2M—pancreatitis	1.92e-05	0.000109	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—pancreatitis	1.9e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL5—pancreatitis	1.9e-05	0.000107	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—pancreatitis	1.9e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH4—pancreatitis	1.9e-05	0.000107	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLA2G1B—pancreatitis	1.88e-05	0.000106	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLA2G1B—pancreatitis	1.87e-05	0.000106	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PPP3CA—pancreatitis	1.86e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LPL—pancreatitis	1.86e-05	0.000105	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—pancreatitis	1.83e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—pancreatitis	1.82e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH1B—pancreatitis	1.81e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—A2M—pancreatitis	1.81e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—A2M—pancreatitis	1.81e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL5—pancreatitis	1.8e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Disease—INS—pancreatitis	1.8e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—pancreatitis	1.8e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRSS1—pancreatitis	1.78e-05	0.000101	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—XDH—pancreatitis	1.77e-05	0.0001	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLA2G1B—pancreatitis	1.77e-05	9.98e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—pancreatitis	1.77e-05	9.97e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LPL—pancreatitis	1.76e-05	9.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALDH2—pancreatitis	1.76e-05	9.93e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SPP1—pancreatitis	1.76e-05	9.92e-05	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—pancreatitis	1.75e-05	9.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—pancreatitis	1.73e-05	9.75e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	1.72e-05	9.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MDM2—pancreatitis	1.71e-05	9.66e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—A2M—pancreatitis	1.71e-05	9.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—LPL—pancreatitis	1.71e-05	9.63e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.7e-05	9.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PNLIP—pancreatitis	1.69e-05	9.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRSS3—pancreatitis	1.69e-05	9.53e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GCG—pancreatitis	1.68e-05	9.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HTR2A—pancreatitis	1.67e-05	9.45e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SPP1—pancreatitis	1.67e-05	9.42e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALDH2—pancreatitis	1.66e-05	9.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH1B—pancreatitis	1.65e-05	9.33e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALDH2—pancreatitis	1.65e-05	9.33e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—pancreatitis	1.64e-05	9.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MDM2—pancreatitis	1.62e-05	9.16e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—pancreatitis	1.61e-05	9.1e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HTR2A—pancreatitis	1.59e-05	8.96e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALDH2—pancreatitis	1.56e-05	8.81e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—pancreatitis	1.56e-05	8.78e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—pancreatitis	1.56e-05	8.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—pancreatitis	1.55e-05	8.74e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—pancreatitis	1.54e-05	8.71e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.54e-05	8.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—pancreatitis	1.53e-05	8.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—pancreatitis	1.53e-05	8.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	1.52e-05	8.59e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—XDH—pancreatitis	1.52e-05	8.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MDM2—pancreatitis	1.5e-05	8.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—pancreatitis	1.48e-05	8.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—pancreatitis	1.47e-05	8.29e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—pancreatitis	1.46e-05	8.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—pancreatitis	1.46e-05	8.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLA2G1B—pancreatitis	1.45e-05	8.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—pancreatitis	1.45e-05	8.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH1B—pancreatitis	1.41e-05	7.97e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PDGFA—pancreatitis	1.41e-05	7.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—A2M—pancreatitis	1.4e-05	7.88e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—pancreatitis	1.39e-05	7.85e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.37e-05	7.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GCG—pancreatitis	1.33e-05	7.52e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—pancreatitis	1.33e-05	7.51e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—INS—pancreatitis	1.33e-05	7.5e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—pancreatitis	1.33e-05	7.5e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLA2G1B—pancreatitis	1.32e-05	7.44e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LPL—pancreatitis	1.32e-05	7.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—pancreatitis	1.31e-05	7.38e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—pancreatitis	1.28e-05	7.24e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALDH2—pancreatitis	1.28e-05	7.21e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—A2M—pancreatitis	1.27e-05	7.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—INS—pancreatitis	1.26e-05	7.12e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GCG—pancreatitis	1.26e-05	7.08e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GCG—pancreatitis	1.25e-05	7.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LPL—pancreatitis	1.25e-05	7.05e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	1.25e-05	7.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—pancreatitis	1.24e-05	7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—pancreatitis	1.22e-05	6.87e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	1.2e-05	6.76e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GCG—pancreatitis	1.18e-05	6.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALDH2—pancreatitis	1.17e-05	6.57e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	1.14e-05	6.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLA2G1B—pancreatitis	1.13e-05	6.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—pancreatitis	1.12e-05	6.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.12e-05	6.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MDM2—pancreatitis	1.11e-05	6.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—pancreatitis	1.1e-05	6.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—A2M—pancreatitis	1.09e-05	6.14e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MDM2—pancreatitis	1.05e-05	5.92e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—pancreatitis	1.05e-05	5.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—pancreatitis	1.05e-05	5.9e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—pancreatitis	1.04e-05	5.9e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—pancreatitis	1.03e-05	5.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—pancreatitis	1.02e-05	5.76e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH2—pancreatitis	9.96e-06	5.62e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—pancreatitis	9.9e-06	5.59e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—pancreatitis	9.85e-06	5.56e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—pancreatitis	9.83e-06	5.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—pancreatitis	9.82e-06	5.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	9.8e-06	5.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatitis	9.71e-06	5.48e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GCG—pancreatitis	9.69e-06	5.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—pancreatitis	9.68e-06	5.46e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—pancreatitis	9.63e-06	5.43e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—pancreatitis	9.44e-06	5.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—pancreatitis	9.39e-06	5.3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—pancreatitis	9.39e-06	5.3e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—pancreatitis	9.29e-06	5.24e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—pancreatitis	8.99e-06	5.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—pancreatitis	8.95e-06	5.05e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	8.94e-06	5.04e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—pancreatitis	8.91e-06	5.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GCG—pancreatitis	8.83e-06	4.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—pancreatitis	8.73e-06	4.93e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ALB—pancreatitis	8.65e-06	4.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—pancreatitis	8.53e-06	4.81e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—pancreatitis	8.3e-06	4.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—pancreatitis	8.23e-06	4.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—pancreatitis	7.87e-06	4.44e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—pancreatitis	7.87e-06	4.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—pancreatitis	7.71e-06	4.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—pancreatitis	7.64e-06	4.31e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatitis	7.64e-06	4.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—pancreatitis	7.6e-06	4.29e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—pancreatitis	7.57e-06	4.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GCG—pancreatitis	7.55e-06	4.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—pancreatitis	7.49e-06	4.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MDM2—pancreatitis	7.45e-06	4.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—pancreatitis	7.32e-06	4.13e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—pancreatitis	7.19e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—pancreatitis	7.18e-06	4.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—pancreatitis	7.14e-06	4.03e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—pancreatitis	7.05e-06	3.98e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—pancreatitis	7.04e-06	3.97e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—pancreatitis	6.93e-06	3.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALB—pancreatitis	6.87e-06	3.88e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—pancreatitis	6.78e-06	3.83e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—pancreatitis	6.78e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—pancreatitis	6.65e-06	3.75e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALB—pancreatitis	6.47e-06	3.65e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALB—pancreatitis	6.45e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALB—pancreatitis	6.1e-06	3.44e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—pancreatitis	6.07e-06	3.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—pancreatitis	5.92e-06	3.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—pancreatitis	5.81e-06	3.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—pancreatitis	5.76e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—pancreatitis	5.66e-06	3.19e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—pancreatitis	5.65e-06	3.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—pancreatitis	5.58e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—pancreatitis	5.55e-06	3.13e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—pancreatitis	5.51e-06	3.11e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—pancreatitis	5.44e-06	3.07e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—pancreatitis	5.33e-06	3.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—pancreatitis	5.19e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—pancreatitis	5.06e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALB—pancreatitis	4.99e-06	2.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—pancreatitis	4.96e-06	2.8e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—pancreatitis	4.81e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALB—pancreatitis	4.55e-06	2.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—pancreatitis	4.37e-06	2.46e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—pancreatitis	4.32e-06	2.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—pancreatitis	4.24e-06	2.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—pancreatitis	4.09e-06	2.3e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—pancreatitis	3.98e-06	2.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—pancreatitis	3.91e-06	2.21e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALB—pancreatitis	3.89e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—pancreatitis	3.4e-06	1.92e-05	CbGpPWpGaD
